125 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
activities for APX3330 and PS, higher payroll costs including stock-based compensation, and other operating expenses. These were offset by a decrease
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
and/or products sufficient to meet its objectives or even to offset the associated transaction and maintenance costs.
In addition, if Ocuphire undertakes
8-K
EX-99.1
k1utmvs6
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.1
5zdd d0f9v5
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
EX-99.1
r2k gkqeccf57s0u8c9
4 Nov 22
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
4:39pm
424B5
yd9qe7mg
7 Jun 21
Prospectus supplement for primary offering
4:21pm
DEFA14A
f6p10t8bvp e82se1o
26 Apr 21
Additional proxy soliciting materials
4:09pm